This medication is used to address a range of conditions marked by increased physiological stress caused by susceptible fungi and yeast, applied across domains where additional symptomatic support is needed, particularly for systemic and mucosal fungal infections. The application of this medication is recognized within these therapeutic contexts.

Flucoran is commonly used to help with conditions characterized by periods of heightened symptoms stemming from various types of candidiasis, including vaginal, oropharyngeal, and esophageal infections, as well as severe systemic mycoses such as Cryptococcal meningitis and candidemia. It may be part of symptomatic management in situations where risk reduction is the goal, assisting in addressing serious fungal infections in high-risk, immunocompromised patients.

The therapeutic benefit assists with managing symptoms related to inflammatory or irritative states such as pain, burning, and difficulty swallowing.

---

Quick Fact: Symptom Management for Fungal Infections
Use Context	Applied in scenarios where additional management of discomfort is required due to recurrent mucosal or genital thrush.
Symptom Domain	Helps address symptoms related to inflammatory or irritative states that interfere with daily comfort.
Benefit	May support the patient during difficult episodes and is relevant for managing symptoms that interfere with daily comfort.

Regulatory References

1. NIH MedlinePlus Drug Information

Absolute Contraindications (Who Must Not Use Flucoran)

Flucoran (Fluconazole) is contraindicated and must not be used in patients with known hypersensitivity to the drug or any other Azole antifungal agent. Furthermore, regulatory labeling absolutely prohibits co-administration with other medications known to prolong the QT interval and metabolized by the CYP3A4 enzyme (e.g., Cisapride, Astemizole, Pimozide, Quinidine), due to the risk of serious cardiac events.

---

Condition-Based and Population Restrictions

Age and Organ Function: Flucoran is approved for use in adults and most pediatric patients (including neonates). Use in older adults and patients with impaired renal function is permitted but requires dose modification if their creatinine clearance is leq 50 mL/min [Source 2.3]. Caution and close monitoring are required for patients with liver dysfunction or pre-existing cardiac risk factors (e.g., uncorrected electrolyte abnormalities).

Pregnancy and Lactation: Use of Flucoran is generally not recommended in pregnancy for non-life-threatening infections. Chronic, high-dose use (e.g., 400 mg to 800 mg per day) during the first trimester is restricted due to associated fetal harm reported in regulatory documents. It passes into breast milk, and caution is advised when prescribing to a nursing woman [Source 3.4].

Interactions with other medicines and products

Flucoran (Fluconazole) is officially documented to interact with many medicinal products, primarily by influencing their plasma concentrations or amplifying the risk of specific cardiac effects.

Contraindicated Combinations

Co-administration is contraindicated with certain medicines due to the risk of serious cardiac events, including prolongation of the QT interval and Torsades de Pointes. The explicit list of forbidden substances in official labeling includes: cisapride, astemizole, pimozide, quinidine, and erythromycin. The use of terfenadine is also contraindicated when Flucoran is administered at doses of 400 mg per day or greater. The combination with halofantrine is officially not recommended due to the potential for increased cardiotoxicity.

Pharmacokinetic Interactions (Exposure Modification)

Flucoran is documented as an inhibitor of cytochrome P450 (CYP) enzymes, specifically a potent inhibitor of CYP2C9 and a moderate inhibitor of CYP3A4 and CYP2C19. This inhibitory action increases the plasma concentration of many co-administered medicines, including: warfarin (increasing bleeding risk), oral hypoglycemics (sulfonylureas like glipizide), phenytoin, statins (HMG-CoA Reductase Inhibitors), immunosuppressants (e.g., tacrolimus, cyclosporine), and certain benzodiazepines (e.g., midazolam).

Conversely, co-administration with rifampicin results in a 25% decrease in the exposure of Flucoran itself, a finding documented in regulatory data. The concurrent use of hydrochlorothiazide is associated with an official increase in Flucoran's exposure.

Connection to the Overall Interaction Profile

The regulatory interaction profile is structured around the drug’s significant potential to alter the exposure of co-administered substances via its CYP enzyme inhibition. This key pharmacokinetic effect dictates the management of numerous co-administrations by requiring careful monitoring and forms the basis for the official prohibition of combinations that pose additive cardiac risks.

Selective Inhibition of Fungal Sterol Synthesis

Flucoran exerts its primary effect by selective inhibition of the fungal enzyme cytochrome P450 14alpha-demethylase (CYP51). This interference halts the crucial conversion of lanosterol to ergosterol, an essential sterol for the structural integrity and function of the fungal cell membrane. The resulting depletion of ergosterol and buildup of toxic sterol precursors destabilizes the fungal cell, which results in compromised fungal growth and replication capacity.

Structural Compromise of the Fungal Membrane

The disruption of ergosterol biosynthesis leads to the incorporation of aberrant sterols into the fungal plasma membrane. This molecular alteration severely compromises the membrane's structure, fluidity, and selective permeability. The loss of selective permeability and structural integrity results in the inability of the fungal cell to regulate its internal environment, contributing to fungistasis or cell death.

Modulation of Fungal Cell Wall Integrity

Beyond the primary membrane effects, the molecular stress caused by Flucoran indirectly triggers a cell wall integrity response in susceptible fungi. This cascade of events leads to changes in the fungal cell wall's protein composition and its mechanical strength. These downstream mechanistic changes augment the primary effect on the cell membrane, altering the integrity and structural strength of the cell wall.

How to Use Flucoran

Flucoran (Fluconazole) is administered according to standardized clinical protocols. Its primary administration routes are oral (using tablets, capsules, or suspension) and intravenous (IV) (using a sterile solution), with the total daily dose remaining the same regardless of the route used. This equivalence allows for smooth transition between inpatient IV therapy and outpatient oral dosing.

---

Standard Dosing Principles

Usage typically involves initiating therapy with a loading dose on Day 1, which is often double the standard maintenance dose, followed by once-daily dosing. Maintenance dosing varies, ranging from 50 mg to 400 mg daily depending on the specific condition. A single oral dose of 150 mg is the standard regimen for acute vaginal candidiasis. The duration of treatment is determined by the specific indication and ranges from a single course to long-term maintenance (e.g., to prevent relapse of cryptococcal meningitis). Oral forms of Flucoran may be taken with or without food as the absorption rate is highly predictable and not clinically impacted by meal timing.

---

Administration and Adjustment Rules

Usage Domain	Clinical Parameters
IV Infusion Rate	Must not exceed 10 mL/minute (maximum 200 mg/hour).
Renal Impairment	Dose must be reduced by 50% for adults with creatinine clearance ≤ 50 mL/min (after the initial full dose).
Pediatric Dosing	Generally administered on a mg/kg basis, with intervals adjusted for neonates (e.g., every 72 or 48 hours for the first month of life).
Oral Preparation	The powder for oral suspension requires reconstitution and must be accurately measured before administration.
Missed Dose Handling	If a patient misses a dose, they should take it when remembered, unless it is near the next scheduled dose, in which case the missed dose is skipped.

These instructions structure the use of the medicine by providing procedural and dosing parameters for administration.

Research evidence / Overview of Studies for Flucoran

---

Evidence for Use in Mucosal Fungal Infections

Research has explored the use of Flucoran in the treatment of fungal infections affecting the mouth and throat (oropharyngeal candidiasis) and the food pipe (esophageal candidiasis). These studies have primarily taken the form of short-term randomized controlled trials (RCTs). The outcomes tracked in these studies related to outcomes linked to inflammatory or irritative states, such as the resolution of pain, burning, and difficulty swallowing. Findings from these clinical studies were associated with measurements of fungal clearance and symptom resolution in the study populations. Further long-term prevention trials were also conducted, and findings describe patterns observed where continuous use was monitored against placebo in high-risk groups, and the research describes patterns of recurrence observed.

Evidence for Use in Systemic and Bloodstream Infections

Flucoran was evaluated in major clinical trials for its use in serious, systemic fungal infections, including when the Candida fungus has entered the bloodstream. These large-scale studies included comparative RCTs against other systemic antifungal drug classes. The key outcomes related to systemic or functional imbalance that were monitored included all-cause survival rates, the overall clinical success of the treatment, and the time required to clear the fungus from the blood cultures. Studies also tracked measurements of survival and clinical success rates that were within predetermined margins when compared to other treatments. Research has been conducted in observational settings evaluating daily-life functioning, contributing to the understanding of the medicine's role in the broader evidence landscape.

What is Still Uncertain About Flucoran Research

Research provides insight into short-term changes, but the evidence highlights what is known—and what is still uncertain. Evidence quality varies across studies, and researchers continue to focus on several key areas where data are less conclusive. The primary limitations include: Research continues to explore the association between prolonged exposure and the isolation of less susceptible Candida and Cryptococcus strains. Additionally, data for certain highly specific subgroups, such as patients with multiple complex comorbidities, remain insufficient or findings were mixed across different centers. Research does not determine whether an individual will respond similarly, but rather contributes to the broader evidence landscape by describing group patterns observed so far.

Key Studies & References

1. Fluconazole Accord capsule, hard ENG Public Assessment Report (EMA/HPRA)

Common questions about Flucoran (FAQ)

Q: What is Flucoran and how does it work?

Flucoran is an antifungal medicine that belongs to a class of drugs called triazoles. The active ingredient is fluconazole.

It works by slowing the growth of fungi that cause infection. Fungi need a substance called ergosterol to build their cell membranes. Flucoran stops the fungus from making ergosterol, which causes the fungal cell to become leaky and stop growing.

---

Q: What is Flucoran used to treat?

Flucoran is used to treat a variety of fungal and yeast infections caused by the Candida species and others. This includes:

• Vaginal yeast infections (vaginal candidiasis).
• Thrush (oropharyngeal and esophageal candidiasis), which are infections of the mouth and throat.
• Systemic infections that can affect the blood, urinary tract, lungs, and other organs.
• Cryptococcal meningitis, which is a fungal infection of the membranes covering the brain and spine.

It may also be used to prevent candidiasis in patients with a weakened immune system, such as those undergoing chemotherapy or radiation therapy before a bone marrow transplant.

---

Q: Is Flucoran the same as Fluconazole?

Yes, Fluconazole is the active ingredient (generic name) in the medicine. Flucoran is a brand name for a medicine that contains fluconazole.

Fluconazole is available as tablets and as a liquid suspension for oral use.

---

Q: How long does it take for Flucoran to start working?

You should begin to feel better during the first few days of treatment. However, the length of treatment varies greatly depending on the type and severity of the infection being treated. For some conditions, you may only need a single dose, while others may require several weeks or even months of treatment.

It is important to continue taking Flucoran for the full duration prescribed by your doctor, even if your symptoms improve quickly.

---

Q: What are the most common side effects of Flucoran?

The most common side effects of Flucoran (fluconazole) are usually mild and may include:

• Headache
• Dizziness
• Diarrhea
• Stomach pain or upset stomach
• Nausea
• Changes in the ability to taste food

If these side effects are severe or do not go away, you should talk to your doctor.

---

Q: Are there any serious side effects I should watch for?

Yes, some side effects are serious and require immediate medical attention. Call your doctor or get emergency help right away if you experience any of the following:

• Signs of a serious allergic reaction: Rash, blistering or peeling skin, hives, itching, or swelling of the face, throat, tongue, lips, eyes, hands, or lower legs, and difficulty breathing.
• Signs of liver injury: Unusual bruising or bleeding, extreme tiredness, lack of energy, loss of appetite, pain in the upper right part of the stomach, dark urine, pale stools, or yellowing of the skin or eyes (jaundice).
• Flu-like symptoms (fever, body aches) or seizures.

---

Q: Can I drink alcohol while taking Flucoran?

It is generally not recommended to drink alcohol while taking Flucoran because the combination may increase the risk of damage to your liver. Flucoran itself can cause liver problems in some people, and alcohol consumption can worsen this effect.

The storage and disposal of Flucoran (Fluconazole) must adhere to official regulatory conditions to maintain stability and safety.

Required Storage Conditions

Flucoran must be stored at Controlled Room Temperature, generally defined as below 30 C (86 F), and must be protected from light and moisture. The medicine must be kept in the original container and the container must remain tightly closed when not in use. Specific liquid forms, including the intravenous solution, must be kept from freezing.

Stability and Child Safety

For the reconstituted oral suspension, stability is limited, and the product must be discarded after 14 days. All forms of Flucoran must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused medicine should be disposed of primarily through an authorized drug take-back program. If this option is unavailable, the product must be mixed with an unappealing substance, sealed in a container, and placed in the household trash, avoiding disposal via wastewater.